Assignee
BETTA PHARMACEUTICALS CO LTD
CN·14 granted patents·39 pending applications·8 citations·filing 2012–2024
Top patents by PatentIndex Score
53 records- 0189US11365196B2FGFR inhibitor and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2018·Granted Jun 21, 2022·6 cites·33 claims
- 0276US11845762B2Compound functioning as bromodomain protein inhibitor, and compositionBETTA PHARMACEUTICALS CO LTD·Filed 2022·Granted Dec 19, 2023·0 cites·8 claims
- 0373US2025223286A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2024·Application pending·0 cites
- 0472US11053238B2Benzimidazole derivatives, preparation methods and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2017·Granted Jul 6, 2021·1 cites·33 claims
- 0571US10059688B2Protein tyrosine kinase modulators and methods of useBETTA PHARMACEUTICALS CO LTD·Filed 2017·Granted Aug 28, 2018·1 cites·19 claims
- 0660US2024352053A1Salt and crystal form of egfr inhibitor, and composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0760US2025051301A1Mutant idh1 and idh2 inhibitor and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0860US2016235757A1Icotinib-containing topical skin pharmaceutical compositions and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2014·Application pending·0 cites
- 0960US2025361241A1Hpk1 inhibitor and medical use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1060US2025223300A1Macrocyclic compound and pharmaceutical composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1158US12043622B2Crystal form of compound for inhibiting the activity of CDK4/6 and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Granted Jul 23, 2024·0 cites·9 claims
- 1258US2025042853A1Bicyclic compound and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1358US2019321369A1Icotinib-containing topical skin pharmaceutical compositions and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 1458US2024342169A1Use of ensartinib or salt thereof in treatment of disease carrying met 14 exon skipping mutationBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1557US2025154149A1Pharmaceutical composition and method for preparing active ingredient compound thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1656US12187713B2Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Granted Jan 7, 2025·0 cites·20 claims
- 1755US9783524B2Protein tyrosine kinase modulators and methods of useBETTA PHARMACEUTICALS CO LTD·Filed 2014·Granted Oct 10, 2017·0 cites·9 claims
- 1855US2024336594A1Six-membered aryl or heteroaryl amides, and composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1955US2024246994A1Polymorph Of Imidazolidinone Compound, Preparation Method Therefor And Use ThereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2055US2024299380A1Application of compound in preparation of drug for treating myelofibrosis and related symptoms/signs thereof, and use of compoundBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2155US2023321100A1Cd73 inhibitor and application thereof in medicineBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 2254US9688687B2Polymorphic forms of icotinib phosphate and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2014·Granted Jun 27, 2017·0 cites·25 claims
- 2354US2024327518A1Anti-pd-l1 nanobody and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2453US11466034B2Compound functioning as bromodomain protein inhibitor, and compositionBETTA PHARMACEUTICALS CO LTD·Filed 2018·Granted Oct 11, 2022·0 cites·22 claims
- 2553US9611272B2Polymorphic forms of icotinib and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2014·Granted Apr 4, 2017·0 cites·20 claims
- 2653US9085588B2Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereofBETTA PHARMACEUTICALS CO LTD·Filed 2012·Granted Jul 21, 2015·0 cites·32 claims
- 2753US2024383974A1Bispecific antibody and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2853US2021340142A1Salt form and crystal form of novel azatricyclic compound and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 2952US2023339882A1Shp2 inhibitor and composition and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3051US2023391779A1Bicyclic compounds, compositions and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3151US2023192705A1Shp2 inhibitors, compositions and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3250US2022227796A1Egfr inhibitors, compositions and methods there ofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3350US2023203055A1Fused ring compound and application thereof in medicineBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3450US2023133169A1Egfr inhibitor, composition, and method for preparation thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3550US2024174681A1Salt and crystalline forms of fgfr4 inhibitor and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3650US2023053342A1Imidazolidinone compound, preparation method therefor and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3749US2023062486A1Kras g12c inhibitor and pharmaceutical use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3849US2023131025A1Quinolyl phosphine oxide compound, and composition and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3949US2022402948A1Egfr inhibitor, composition and preparation method thereforBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4047US9505774B2Polymorphic forms of icotinib maleate and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2014·Granted Nov 29, 2016·0 cites·24 claims
- 4147US2022064196A1EGFR Inhibitors, Compositions and Methods ThereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4245US2022259235A1EGFR Inhibitor, Composition, and Preparation Method ThereforBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4344US2021395256A1Tyrosine kinase inhibitors, compositions and methods there ofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 4444US2023219890A1Bicyclic compounds and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 4543US2023219956A1Quinazoline compound and pharmaceutical application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4643US2021269440A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 4742US2021300909A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 4842US2022119411A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 4942US2022041583A1Immunomodulators, compositions and methods there ofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 5042US2022002307A1Fgfr4 inhibitor and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BETTA PHARMACEUTICALS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →